BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Operating cash flow 2016–2025
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$7.0MFY2025 · since FY2016: -$5.9M → -$7.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.0M | +23.3% |
| FY2024 | -$9.1M | +55.6% |
| FY2023 | -$20.5M | -5.9% |
| FY2022 | -$19.3M | +26.4% |
| FY2021 | -$26.3M | +25.4% |
| FY2020 | -$35.2M | -212.9% |
| FY2019 | -$11.2M | +9.2% |
| FY2018 | -$12.4M | -424.0% |
| FY2017 | -$2.4M | +59.6% |
| FY2016 | -$5.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BCLI financial trends
BCLI RevenueBCLI Net incomeBCLI Net marginBCLI Gross profitBCLI Gross marginBCLI Operating incomeBCLI Operating marginBCLI Free cash flowBCLI Capital expendituresBCLI Return on equityBCLI Stock buybacksBCLI Dividends paidBCLI Total assetsBCLI Total liabilitiesBCLI Shareholders’ equityBCLI overview →